文献速递肾癌与肾肿瘤

嫌色细胞肾细胞癌分级:纳入凝固性肿瘤坏死的四級分类证据

Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
PubMed 文献 · Eur Urol · 2020-11-07

该研究回顾性分析了266例非转移性嫌色细胞肾细胞癌(ChRCC)肾切除术患者,验证Paner分级系统并扩展为纳入肿瘤坏死的四級方案。结果显示Paner分级与癌症特异性生存(CSS)显著相关,将2级按坏死有无拆分后,2、3、4级风险比分别为4.63(p=0.007)、17.8(p<0.001)、20.9(p<0.001),提示四級系统可更好区分预后。

要点

  • Paner分级与ChRCC患者CSS显著相关,包括1级与2级之间的差异。
  • 在2级患者中,肿瘤坏死存在与否可区分CSS更差的患者。
  • 四級系统(2级按坏死拆分)的风险比随级别升高,与WHO/ISUP其他RCC四級系统一致。

核心结论

  • 将Paner三級ChRCC分级扩展为纳入肿瘤坏死的四級系统,能进一步区分患者预后,有助于术后患者咨询。
  • 四級ChRCC分级与WHO/ISUP对透明细胞和乳头状RCC的四級分级系统在级数上保持一致。

研究设计与样本

  • 回顾性队列研究,纳入1970至2012年间因非转移性ChRCC接受肾切除术的266例患者。
  • 按Paner系统评估ChRCC分级,并评估凝固性肿瘤坏死。

主要发现

  • Paner分级与CSS显著相关,包括1级与2级肿瘤之间的结局差异。
  • 在2级肿瘤患者中,肿瘤坏死存在与更差CSS相关。
  • 扩展四級系统中,2级、3级、4级肿瘤与CSS关联的风险比分别为4.63(p=0.007)、17.8(p<0.001)、20.9(p<0.001)。

关键数值与推荐

  • Paner分级系统(三級)与CSS显著相关。
  • 四級系统将Paner 2级拆分为有和无肿瘤坏死两组。
  • 2级、3级、4级风险比分别为4.63(p=0.007)、17.8(p<0.001)、20.9(p<0.001)。

临床怎么用

  • 对ChRCC术后标本进行Paner分级并评估凝固性肿瘤坏死,采用四級系统可增强预后分层和患者咨询。

局限性

  • 研究缺乏纳入其他病理特征的多变量分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although grading systems have been proposed for chromophobe renal cell carcinoma (ChRCC), including a three-tiered system by Paner et al (Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 2010;34:1233-40), none have gained clinical acceptance, and the World Health Organization (WHO) currently recommends against grading ChRCC. OBJECTIVE: To validate a previously published grading scheme and propose a scheme that includes tumor necrosis. DESIGN, SETTING, AND PARTICIPANTS: A total of 266 patients who underwent nephrectomy for nonmetastatic ChRCC between 1970 and 2012 were reviewed for ChRCC grade according to the Paner system and coagulative tumor necrosis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations with cancer-specific survival (CSS) were evaluated using Cox proportional hazard regression models and summarized with hazard ratios (HRs). RESULTS AND LIMITATIONS: Twenty-nine patients died from RCC; the median follow-up was 11.0 (interquartile range 7.9-15.9) yr. ChRCC grade according to the Paner system was significantly associated with CSS, including the difference in outcome between grade 1 and 2 tumors. Among patients with grade 2 tumors, the presence of tumor necrosis helped delineate patients with worse CSS. As such, the Paner system was expanded to four tiers separating grade 2 into those with and without tumor necrosis. HRs for associations of the proposed grade 2, 3, and 4 tumors with CSS were 4.63 (p=0.007), 17.8 (p<0.001), and 20.9 (p<0.001), respectively. The study is limited by the lack of multivariable analysis including additional pathologic features. CONCLUSIONS: The expansion of a previously reported ChRCC grading system from three to four tiers by the inclusion of tumor necrosis helps further delineate patient outcome and can, therefore, enhance patient counseling following surgery. It also aligns the number of ChRCC grades with the WHO/International Society of Urologic Pathology four-tiered grading systems for clear cell and papillary RCC. PATIENT SUMMARY: Chromophobe renal cell carcinoma is the third most common type of renal cancer, and unlike other renal cancers, there is no accepted prognostic grading system. In this study, we found that a grading system that included a pathologic feature of tumor necrosis could better define outcomes for patients with chromophobe renal cell carcinoma.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Avulova S, Cheville JC, Lohse CM, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol. 2020. PMID: 33172723. doi:10.1016/j.eururo.2020.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。